Table 1.

The use of organoids for chemotherapy sensitivity testing in TNBC.

Therapeutic Agents	Dose Ranges/IC50 Values	Main Results	References
Circular RNA	1.17–8.24 μM	Doxorubicin sensitivity increase	[35]
Decitabine	100 nM	DNMT protein level correlates with decitabine efficacy	[36]
Docetaxel, Epirubicin	Docetaxel dose: 1 nM Epirubicin logIC50 values =  0.3728 μM, 26.7300 μM	Decreased TNBC organoids’ viability Consistency of clinical response and response of tissue-derived organoids	[29,31]
Multiple Agents	20 μM–27.4 nM	High patient-derived organoid pharmaco-phenotyping association with clinical outcomes and previous treatment responses Patient-specific sensitivity predication for personalized therapy by patient-derived organoid pharmaco-phenotyping	[30]
MuV-U-Japan	Multiplicity of infection = 0–10	Potent killing effect in chemotherapy-resistant TNBC patient-derived xenograft organoids	[37]
Paclitaxel, Romidepsin, Trametinib	IC50 values = 10,500, 18,000 +/− 12.6, 6.5–24.9 μM	Organoid growth inhibition High IC50 paclitaxel value in TNBC patient-derived xenograft organoids CD44 and E-cadherin downregulation Enhanced apoptosis induction after SYTL4 knockdown	[32,33,34]